Search

Your search keyword '"Liu, Guang-yu"' showing total 410 results

Search Constraints

Start Over You searched for: Author "Liu, Guang-yu" Remove constraint Author: "Liu, Guang-yu"
410 results on '"Liu, Guang-yu"'

Search Results

4. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial

16. Neoadjuvant Anthracycline Followed by Toripalimab Combined with Nab-Paclitaxel in Patients with Early Triple-Negative Breast Cancer (NeoTENNIS): A Single-Arm, Phase II Study

29. Handover of anesthesia care is associated with an increased risk of delirium in elderly after major noncardiac surgery: results of a secondary analysis

32. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study

33. A Novel Failure-Distribution-Dependent Non-Fragile <inline-formula><tex-math notation="LaTeX">$H_\infty$</tex-math></inline-formula> Fault-Tolerant Load Frequency Control for Faulty Multi-Area Power Systems

34. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

35. Abstract OT3-27-01: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial

41. Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study

44. HSP90 N‐terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2‐driven breast cancer progression

45. L-tetrahydropalamatine inhibits tumor necrosis factor-α-induced monocyte-endothelial cell adhesion through downregulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 involving suppression of nuclear factor-κ B signaling pathway

47. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Catalog

Books, media, physical & digital resources